Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2013

View Archived Issues

Activity of AXL/c-Met inhibitor CEP-40783 described in vitro and in vivo

Bayer Schering Pharma synthesizes new Mnk1 inhibitors for cancer

Cubist completes acquisition of Optimer Pharmaceuticals

Amgen reports active third quarter 2013

Merck Serono and Selvita enter oncology collaboration targeting metabolic pathways

Merck & Co. plans BLA submission for multivalent HPV vaccine

Intranasal formulation of teriparatide may improve compliance

Shire announces reorganization progress of third quarter 2013

Potent, small-molecule, pyridopyrimidinone inhibitor of schwannoma tumorigenesis described

Development and characterization of a first-in-class bacterial inhibitor

Clinical trials show efficacy of netupitant/palonosetron combination

FDA committee supports approval of simeprevir as part of combination therapy for hepatitis C

FDA approves GE Healthcare's brain imaging drug for Alzheimer's disease and dementia

Five Prime provides update on two antibody candidates entering phase I trials

Pfizer discloses new DGAT2 inhibitors

Novel stem cell microparticles claimed by ReNeuron

New chimeric/humanized antibodies bind to human tau protein

Tissue Therapies files application to conduct pivotal VitroGro ECM trial

NovelMed Therapeutics divulges new monoclonal antibodies

Novel nucleic acid vectors presented by Columbia University

ViiV Healthcare files single-tablet regimen MAA for people living with HIV

Imugene executes sale and purchase agreement to acquire Biolife Science

Zohydro ER approved by the FDA for pain

EMA committee recommends approval of Lundbeck's Brintellix

CHMP issues opinion on compassionate use of Gilead's sofosbuvir for chronic HCV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...